A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Severe cardiovascular disease such as unstable angina or poorly controlled hypertension Increased intracranial or intraocular pressure (however these remain controversial, with recent studies suggesting otherwise) Poorly controlled psychosis Severe liver disease such as cirrhosis Pregnancy Active substance use disorder (for serial ketamine injections) Age less than 3 months
==== European Union ==== The European Food Safety Authority (EFSA) in 2016 reviewed the current evidence, finding the relationship between serum 25(OH)D concentration and musculoskeletal health outcomes is widely variable. They considered that average requirements and population reference intake values for vitamin D cannot be derived and that a serum 25(OH)D concentration of 50 nmol/L was a suitable target value. For all people over the age of 1, including women who are pregnant or lactating, they set an adequate intake of 15 μg/day (600 IU). On the other hand, the EU Commission defined nutrition labelling for foodstuffs as regards recommended daily allowances (RDA) for vitamin D to 5 μg/day (200 IU) as 100%. The EFSA reviewed safe levels of intake in 2012, setting the tolerable upper limit for adults at 100 μg/day (4000 IU), a similar conclusion as the IOM. The Swedish National Food Agency recommends a daily intake of 10 μg (400 IU) of vitamin D3 for children and adults up to 75 years, and 20 μg (800 IU) for adults 75 and older. Non-government organisations in Europe have made their own recommendations. The German Society for Nutrition recommends 20 μg. The European Menopause and Andropause Society recommends postmenopausal women consume 15 μg (600 IU) until age 70, and 20 μg (800 IU) from age 71. This dose should be increased to 100 μg (4,000 IU) in some patients with very low vitamin D status or in case of co-morbid conditions.
=== Therapy === After his period of psychological transformation and his later discovery of alchemy, Jung saw analysis as more of a tool for personal growth than treatment for certain mental disorders. Whereas Freud mainly gleaned or tested his theories on a small group of upper-middle-class patients, mainly women suffering from (what was thought to be at the time) hysteria, Jung had seen patients from all walks of life and with a huge diversity of diagnoses.Jung believed psychosis (schizophrenia) and neurosis (hysteria) to be extreme expressions of the two basic attitudinal types. The psychotic patient's libido has withdrawn so far from external reality that they inhabit a private world of fantasy and archetypal imagery (the unconscious). The neurotic patient's libido has been directed so far away from internal reality that they become hugely preoccupied with their own influence on the world and social relationships (i.e., they live in their persona). In this sense, Jung saw all mental illness as forms of imbalance. He also saw mental illness as a creative act, in that it is a product of the individuation process whereby the psyche is continuing to grow and develop in abnormal psychic circumstances. Thus, the purpose of psychotherapy, for Jung, was individuation and to find a more balanced mode of existence. Influenced by Freud's psychoanalysis, Jung saw the analysis of dreams as essential to Jungian analysis. However, particularly after his separation from Freud, Jung's ideas surrounding dreams departed in significant ways from Freud's theory.
The two substrates of this enzyme are (S)-malic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). its products are pyruvic acid, carbon dioxide, and reduced NADPH. This enzyme belongs to the family of oxidoreductases, to be specific those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-malate:NADP+ oxidoreductase (oxaloacetate-decarboxylating). This enzyme participates in pyruvate metabolism and carbon fixation. NADP-malic enzyme is one of three decarboxylation enzymes used in the inorganic carbon concentrating mechanisms of C4 and CAM plants. The others are NAD-malic enzyme and PEP carboxykinase. Although often one of the three photosynthetic decarboxylases predominate, the simultaneous operation of all three is also shown to exist.
However, the Polish government headed by the Law and Justice party maintained that the reforms were necessary due to the prevalence of corruption within the Polish judiciary and the continued presence of holdover Communist era judges. In October 2019, Poland's governing Law and Justice party (PiS) won parliamentary election, keeping its majority in the lower house. The second was centrist Civic Coalition (KO). The government of Prime Minister Mateusz Morawiecki continued. However, PiS leader Jarosław Kaczyński was considered the most powerful political figure in Poland although not a member of government. In July 2020, President Andrzej Duda, supported by PiS, was re-elected. Poland was one of neighbouring Ukraine's most ardent supporters after the 2022 Russian invasion of Ukraine. As of November 2022, Poland had received more than 1.5 million Ukrainian refugees since the beginning of the war. In September 2023, however, Poland said that it would stop supplying arms to Ukraine and instead focus on its own defense. Poland's decision to ban importing Ukrainian grain, in order to protect its own farmers, had caused tension between the two countries. In October 2023, the ruling Law and Justice (PiS) party won the largest share of the vote in the election, but lost its majority in parliament. In December 2023, Donald Tusk became the new Prime Minister to succeed Morawiecki, leading a coalition of three parliamentary groups made up of Civic Coalition, Third Way, and The Left. Law and Justice became the leading opposition party.
Sources: en.wikipedia.org
It was not until the beginning of the 17th century, when Grotius and his successors developed the idea of international law, that the balance of power was formulated as a fundamental principle of diplomacy, although this formulation must have reflected existing practices. In accordance with this new discipline, the European states formed a sort of federal community, the fundamental condition of which was the preservation of a balance of power, i.e., such a disposition of things that no one state, or potentate, should be able absolutely to predominate and prescribe laws to the rest. And, since all were equally interested in this settlement, it was held to be the interest, the right, and the duty of every power to interfere, even by force of arms, when any of the conditions of this settlement were infringed upon, or assailed by, any other member of the community.
In a lecture on 14 September 2007, Dietmar von Reeken described the emergence of a "Lower Saxony consciousness" in the 19th century, the geographical basis of which was used to invent a territorial construct: the resulting local heritage societies (Heimatvereine) and their associated magazines routinely used the terms "Lower Saxony" or "Lower Saxon" in their names. At the end of the 1920s in the context of discussions about a reform of the Reich, and promoted by the expanding local heritage movement (Heimatbewegung), a 25-year conflict started between "Lower Saxony" and "Westphalia". The supporters of this dispute were administrative officials and politicians, but regionally focussed scientists of various disciplines were supposed to have fuelled the arguments. In the 1930s, a real Lower Saxony did not yet exist, but there were a plethora of institutions that would have called themselves "Lower Saxon". The motives and arguments in the disputes between "Lower Saxony" and "Westphalia" were very similar on both sides: economic interests, political aims, cultural interests and historical aspects.
=== Marketed === Daridorexant (nemorexant; Quviviq) – dual OX1 and OX2 antagonist – approved for insomnia in January 2022, formerly under development for sleep apnea – half-life 8 hours Fazamorexant (Mengping) – dual OX1 and OX2 antagonist – approved for insomnia in China in May 2026 – half-life 2–4 hours Lemborexant (Dayvigo) – dual OX1 and OX2 antagonist – approved for insomnia in December 2019 and released June 1 2020, under development for circadian rhythm sleep disorders, chronic obstructive pulmonary disease, and sleep apnea – half-life 17–55 hours Suvorexant (Belsomra) – dual OX1 and OX2 antagonist – approved for insomnia in August 2014, under development for delirium – half-life 12 hours Vornorexant (Vorzzz) – dual OX1 and OX2 antagonist – approved for insomnia in Japan in August 2025 – half-life 1.5–3 hours
Caffeine is a stimulant compound belonging to the xanthine class of chemicals naturally found in coffee, tea, and (to a lesser degree) cocoa or chocolate. Caffeine is included in many soft drinks, as well as a larger amount in energy drinks. It is the world's most widely used psychoactive drug and by far the most common stimulant. In North America, 90% of adults consume caffeine daily. A few jurisdictions restrict the sale and use of caffeine. In the United States, the Food and Drug Administration has banned the sale of pure and highly concentrated caffeine products for personal consumption, due to the risk of overdose and death. The Australian Government has announced a ban on the sale of pure and highly concentrated caffeine food products for personal consumption, following the death of a young man from acute caffeine toxicity. In Canada, Health Canada has proposed to limit the amount of caffeine in energy drinks to 180 mg per serving, and to require warning labels and other safety measures on these products. Caffeine is also included in some medications, usually for the purpose of enhancing the effect of the primary ingredient, or reducing one of its side effects (especially drowsiness). Tablets containing standardized doses of caffeine are also widely available. Caffeine's mechanism of action differs from many stimulants, as it produces stimulant effects by inhibiting adenosine receptors. Adenosine receptors are thought to be a large driver of drowsiness and sleep, and their action increases with extended wakefulness.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.